Literature DB >> 21713585

Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010.

P Lozeron1, D Adams.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an uncommon disease of the peripheral nerves. The diagnosis is based mainly on clinical presentation, cerebrospinal fluid (CSF) examination, and electrodiagnostic studies. Treatment of CIDP has at least two components: supportive care and specific therapy including primarily steroids, intravenous immunoglobulins (IVIg), and plasmapheresis (PE). This review summarizes progress in the treatment of CIDP published during the last year.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21713585     DOI： 10.1007/s00415-011-6143-5

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  16 in total

1.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision.

Authors:  P Y K Van den Bergh; R D M Hadden; P Bouche; D R Cornblath; A Hahn; I Illa; C L Koski; J-M Léger; E Nobile-Orazio; J Pollard; C Sommer; P A van Doorn; I N van Schaik
Journal:  Eur J Neurol       Date:  2010-03       Impact factor: 6.089

2.  A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Karine Viala; Thierry Maisonobe; Tanya Stojkovic; Régine Koutlidis; Xavier Ayrignac; Lucile Musset; Emmanuel Fournier; Jean-Marc Léger; Pierre Bouche
Journal:  J Peripher Nerv Syst       Date:  2010-03       Impact factor: 3.494

3.  Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy.

Authors:  Sagiri Isose; Masahiro Mori; Sonoko Misawa; Kazumoto Shibuya; Satoshi Kuwabara
Journal:  J Peripher Nerv Syst       Date:  2010-06       Impact factor: 3.494

4.  Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R A C Hughes; K C Gorson; D Cros; J Griffin; J Pollard; J-M Vallat; S L Maurer; K Riester; G Davar; K Dawson; A Sandrock
Journal:  Neurology       Date:  2010-02-23       Impact factor: 9.910

5.  Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy.

Authors:  Gurdesh Bedi; Andrew Brown; Tao Tong; Khema R Sharma
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-02-22       Impact factor: 10.154

6.  Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial.

Authors:  Ivo N van Schaik; Filip Eftimov; Pieter A van Doorn; Esther Brusse; Leonard H van den Berg; W Ludo van der Pol; Catharina G Faber; Joost C H van Oostrom; Oscar J M Vogels; Rob D M Hadden; Bert U Kleine; Anouk G W van Norden; Jan J G M Verschuuren; Marcel G W Dijkgraaf; Marinus Vermeulen
Journal:  Lancet Neurol       Date:  2010-02-02       Impact factor: 44.182

7.  Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Peter D Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Richard Hughes; Norman Latov; Ingemar Merkies; Pieter van Doorn
Journal:  Arch Neurol       Date:  2010-09

Review 8.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Anthony V Swan; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

9.  A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  D Cocito; I Paolasso; G Antonini; L Benedetti; C Briani; C Comi; R Fazio; S Jann; S Matà; A Mazzeo; M Sabatelli; E Nobile-Orazio
Journal:  Eur J Neurol       Date:  2009-10-23       Impact factor: 6.089

10.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Authors:  Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A van Doorn
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182
View more
  1 in total

1.  Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.

Authors:  Leslie P Cousens; Federico Mingozzi; Sander van der Marel; Yan Su; Richard Garman; Valerie Ferreira; William Martin; David W Scott; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.